Echelon Wealth Partners Comments on Medexus Pharmaceuticals Inc.’s Q2 2024 Earnings (TSE:MDP)

Medexus Pharmaceuticals Inc. (TSE:MDP) – Stock analysts at Echelon Wealth Partners reduced their Q2 2024 earnings per share estimates for Medexus Pharmaceuticals in a report issued on Wednesday, September 6th. Echelon Wealth Partners analyst S. Quenneville now expects that the company will post earnings of $0.05 per share for the quarter, down from their prior estimate of $0.07. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.05 per share. Echelon Wealth Partners also issued estimates for Medexus Pharmaceuticals’ FY2024 earnings at $0.07 EPS.

Separately, Bloom Burton upgraded Medexus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, June 26th.

Medexus Pharmaceuticals Stock Up 7.5 %

TSE:MDP opened at C$3.30 on Friday. The company has a 50 day simple moving average of C$2.53. The company has a market capitalization of C$67.35 million, a price-to-earnings ratio of 15.71 and a beta of 1.76. Medexus Pharmaceuticals has a 12-month low of C$0.88 and a 12-month high of C$3.53.

Medexus Pharmaceuticals (TSE:MDP) last posted its quarterly earnings data on Wednesday, June 21st. The company reported C$0.41 earnings per share for the quarter, topping the consensus estimate of C($0.07) by C$0.48. Medexus Pharmaceuticals had a return on equity of 16.23% and a net margin of 2.80%. The company had revenue of C$38.72 million during the quarter, compared to analysts’ expectations of C$38.17 million.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.